What are the treatment guidelines for mycosis fungoides/Sezary syndrome (MF/SS) in cutaneous T-cell lymphoma (CTCL)?

Updated: Aug 15, 2018
  • Author: Lauren C Pinter-Brown, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

The NCCN recommends that patients be treated at specialized centers with expertise in the management of MF/SS. Unlike other non-Hodgkin lymphoma subtypes, MF/SS criteria have not correlated with prognosis, and treatment decisions are made on a clinical basis. [123]

In 2011, the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the EORTC issued a joint consensus statement proposing new clinical end points and response criteria for use in clinical trials of MF/SS. [126]  The NCCN includes the new criteria in its current recommendations. [123]

All three guidelines recommend treatment selection based on clinical stage. [123, 124, 125]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!